Hostname: page-component-586b7cd67f-vdxz6 Total loading time: 0 Render date: 2024-11-30T15:21:38.040Z Has data issue: false hasContentIssue false

Transcription factors in the pathogenesis of diabetic nephropathy

Published online by Cambridge University Press:  28 April 2009

Amber Paratore Sanchez
Affiliation:
Division of Nephrology, University of California San Diego, La Jolla, CA 92093-0711, USA. Center for Renal Translational Medicine, University of California San Diego/VA Medical System, La Jolla, CA 92093-0711, USA.
Kumar Sharma*
Affiliation:
Division of Nephrology, University of California San Diego, La Jolla, CA 92093-0711, USA. Center for Renal Translational Medicine, University of California San Diego/VA Medical System, La Jolla, CA 92093-0711, USA.
*
*Corresponding author: Kumar Sharma, Center for Renal Translational Medicine, University of California San Diego/VA Medical System, 9500 Gilman Drive, MC 0711, La Jolla, CA 92093-0711, USA. Tel: +1 858 822 0870; Fax: +1 858 822 7483; E-mail: [email protected]

Abstract

Approximately a third of patients with diabetes develop diabetic kidney disease, and diabetes is the leading cause of end-stage renal disease in most developed countries. Hyperglycaemia is known to activate genes that ultimately lead to extracellular matrix accumulation, the hallmark of diabetic nephropathy. Several transcription factors have been implicated in glucose-mediated expression of genes involved in diabetic nephropathy. This review focuses on the transcription factors upstream stimulatory factors 1 and 2 (USF1 and 2), activator protein 1 (AP-1), nuclear factor (NF)-κB, cAMP-response-element-binding protein (CREB), nuclear factor of activated T cells (NFAT), and stimulating protein 1 (Sp1). In response to high glucose, several of these transcription factors regulate the gene encoding the profibrotic cytokine transforming growth factor β, as well as genes for a range of other proteins implicated in inflammation and extracellular matrix turnover, including thrombospondin 1, the chemokine CCL2, osteopontin, fibronectin, decorin, plasminogen activator inhibitor 1 and aldose reductase. Identifying the molecular mechanisms by which diabetic nephropathy occurs has important clinical implications as therapies can then be tailored to target those at risk. Strategies to specifically target transcription factor activation and function may be employed to halt the progression of diabetic nephropathy.

Type
Review Article
Copyright
Copyright © Cambridge University Press 2009

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

References

1Marre, M. (1999) Genetics and the prediction of complications in type 1 diabetes. Diabetes Care 22 Supplement 2, B53-58Google ScholarPubMed
2Chowdhury, T.A. et al. (1999) Genetic determinants of diabetic nephropathy. Clinical Science (London) 96, 221-230CrossRefGoogle ScholarPubMed
3Granier, C. et al. (2008) Gene and protein markers of diabetic nephropathy. Nephrology Dialysis Transplantation 23, 792-799CrossRefGoogle ScholarPubMed
4Wada, J., Makino, H. and Kanwar, Y.S. (2002) Gene expression and identification of gene therapy targets in diabetic nephropathy. Kidney International 61, S73-78CrossRefGoogle ScholarPubMed
5Zhu, Y., Usui, H.K. and Sharma, K. (2007) Regulation of transforming growth factor beta in diabetic nephropathy: implications for treatment. Seminars in Nephrology 27, 153-160CrossRefGoogle ScholarPubMed
6Levine, M. and Tjian, R. (2003) Transcription regulation and animal diversity. Nature 424, 147-151CrossRefGoogle ScholarPubMed
7Frith, M.C. et al. (2008) A code for transcription initiation in mammalian genomes. Genome Research 18, 1-12CrossRefGoogle ScholarPubMed
8Han, I. and Kudlow, J.E. (1997) Reduced O glycosylation of Sp1 is associated with increased proteasome susceptibility. Molecular and Cellular Biology 17, 2550-2558CrossRefGoogle ScholarPubMed
9Weigert, C. et al. (2004) Upstream stimulatory factor (USF) proteins induce human TGF-beta1 gene activation via the glucose-response element-1013/-1002 in mesangial cells: up-regulation of USF activity by the hexosamine biosynthetic pathway. Journal of Biological Chemistry 279, 15908-15915CrossRefGoogle ScholarPubMed
10Kreisberg, J.I., Radnik, R.A. and Kreisberg, S.H. (1996) Phosphorylation of cAMP responsive element binding protein after treatment of mesangial cells with high glucose plus TGF beta or PMA. Kidney International 50, 805-810CrossRefGoogle ScholarPubMed
11Liu, L., Li, Y. and Tollefsbol, T.O. (2008) Gene-environment interactions and epigenetic basis of human diseases. Current Issues in Molecular Biology 10, 25-36Google ScholarPubMed
12Miao, F. et al. (2007) Genome-wide analysis of histone lysine methylation variations caused by diabetic conditions in human monocytes. Journal of Biological Chemistry 282, 13854-13863CrossRefGoogle ScholarPubMed
13Villeneuve, L.M. et al. (2008) Epigenetic histone H3 lysine 9 methylation in metabolic memory and inflammatory phenotype of vascular smooth muscle cells in diabetes. Proceedings of the National Academy of Sciences of the United States of America 105, 9047-9052CrossRefGoogle ScholarPubMed
14Brivanlou, A.H. and Darnell, J.E. Jr (2002) Signal transduction and the control of gene expression. Science 295, 813-818CrossRefGoogle ScholarPubMed
15Pabo, C.O. and Sauer, R.T. (1992) Transcription factors: structural families and principles of DNA recognition. Annual Review of Biochemistry 61, 1053-1095CrossRefGoogle ScholarPubMed
16Atchley, W.R. and Fitch, W.M. (1997) A natural classification of the basic helix-loop-helix class of transcription factors. Proceedings of the National Academy of Sciences of the United States of America 94, 5172-5176CrossRefGoogle ScholarPubMed
17Henrion, A.A. et al. (1996) Mouse USF1 gene cloning: comparative organization within the c-myc gene family. Mammalian Genome 7, 803-809CrossRefGoogle ScholarPubMed
18Luo, X. and Sawadogo, M. (1996) Antiproliferative properties of the USF family of helix-loop-helix transcription factors. Proceedings of the National Academy of Sciences of the United States of America 93, 1308-1313CrossRefGoogle ScholarPubMed
19Latchman, D.S. (1997) Transcription factors: an overview. International Journal of Biochemistry and Cell Biology 29, 1305-1312CrossRefGoogle ScholarPubMed
20Shi, L. et al. (2008) High glucose levels upregulate upstream stimulatory factor 2 gene transcription in mesangial cells. Journal of Cellular Biochemistry 103, 1952-1961CrossRefGoogle ScholarPubMed
21Liu, S., Shi, L. and Wang, S. (2007) Overexpression of upstream stimulatory factor 2 accelerates diabetic kidney injury. American Journal of Physiology – Renal Physiology 293, F1727-1735CrossRefGoogle ScholarPubMed
22Zhu, Y. et al. (2005) Role of upstream stimulatory factors in regulation of renal transforming growth factor-beta1. Diabetes 54, 1976-1984CrossRefGoogle ScholarPubMed
23Corre, S. and Galibert, M.D. (2005) Upstream stimulating factors: highly versatile stress-responsive transcription factors. Pigment Cell Research 18, 337-348CrossRefGoogle ScholarPubMed
24Kutz, S.M. et al. (2006) TGF-beta 1-induced PAI-1 expression is E box/USF-dependent and requires EGFR signaling. Experimental Cell Research 312, 1093-1105CrossRefGoogle Scholar
25Wang, S. et al. (2004) Glucose up-regulates thrombospondin 1 gene transcription and transforming growth factor-beta activity through antagonism of cGMP-dependent protein kinase repression via upstream stimulatory factor 2. Journal of Biological Chemistry 279, 34311-34322CrossRefGoogle ScholarPubMed
26Vallet, V.S. et al. (1998) Differential roles of upstream stimulatory factors 1 and 2 in the transcriptional response of liver genes to glucose. Journal of Biological Chemistry 273, 20175-20179CrossRefGoogle ScholarPubMed
27Vallet, V.S. et al. (1997) Glucose-dependent liver gene expression in upstream stimulatory factor 2 -/- mice. Journal of Biological Chemistry 272, 21944-21949CrossRefGoogle ScholarPubMed
28Pan, L. et al. (2001) Critical roles of a cyclic AMP responsive element and an E-box in regulation of mouse renin gene expression. Journal of Biological Chemistry 276, 45530-45538CrossRefGoogle Scholar
29Bidder, M. et al. (2002) Osteopontin transcription in aortic vascular smooth muscle cells is controlled by glucose-regulated upstream stimulatory factor and activator protein-1 activities. Journal of Biological Chemistry 277, 44485-44496CrossRefGoogle ScholarPubMed
30Sirito, M. et al. (1998) Overlapping roles and asymmetrical cross-regulation of the USF proteins in mice. Proceedings of the National Academy of Sciences of the United States of America 95, 3758-3763CrossRefGoogle ScholarPubMed
31Scholtz, B., Kingsley-Kallesen, M. and Rizzino, A. (1996) Transcription of the transforming growth factor-beta2 gene is dependent on an E-box located between an essential cAMP response element/activating transcription factor motif and the TATA box of the gene. Journal of Biological Chemistry 271, 32375-32380CrossRefGoogle Scholar
32Lorenzen, J. et al. (2008) The role of osteopontin in the development of albuminuria. Journal of the American Society of Nephrology 19, 884-890CrossRefGoogle ScholarPubMed
33Hsieh, T.J. et al. (2006) Upregulation of osteopontin gene expression in diabetic rat proximal tubular cells revealed by microarray profiling. Kidney International 69, 1005-1015CrossRefGoogle ScholarPubMed
34Junaid, A. and Amara, F.M. (2004) Osteopontin: correlation with interstitial fibrosis in human diabetic kidney and PI3-kinase-mediated enhancement of expression by glucose in human proximal tubular epithelial cells. Histopathology 44, 136-146CrossRefGoogle ScholarPubMed
35Fischer, J.W. et al. (1998) Upregulation of osteopontin expression in renal cortex of streptozotocin-induced diabetic rats is mediated by bradykinin. Diabetes 47, 1512-1518CrossRefGoogle ScholarPubMed
36Wu, Z. et al. (2004) AP-1 complexes mediate oxidized LDL-induced overproduction of TGF-beta(1) in rat mesangial cells. Cell Biochemistry and Function 22, 237-247CrossRefGoogle ScholarPubMed
37Weigert, C. et al. (2000) AP-1 proteins mediate hyperglycemia-induced activation of the human TGF-beta1 promoter in mesangial cells. Journal of the American Society of Nephrology 11, 2007-2016CrossRefGoogle ScholarPubMed
38Weigert, C. et al. (2002) Angiotensin II induces human TGF-beta 1 promoter activation: similarity to hyperglycaemia. Diabetologia 45, 890-898CrossRefGoogle ScholarPubMed
39Wilmer, W.A. and Cosio, F.G. (1998) DNA binding of activator protein-1 is increased in human mesangial cells cultured in high glucose concentrations. Kidney International 53, 1172-1181CrossRefGoogle ScholarPubMed
40Haneda, M. et al. (2003) Overview of glucose signaling in mesangial cells in diabetic nephropathy. Journal of the American Society of Nephrology 14, 1374-1382CrossRefGoogle ScholarPubMed
41Ramana, K.V. et al. (2004) Activation of nuclear factor-kappaB by hyperglycemia in vascular smooth muscle cells is regulated by aldose reductase. Diabetes 53, 2910-2920CrossRefGoogle ScholarPubMed
42Chen, S. et al. (2003) Differential activation of NF-kappa B and AP-1 in increased fibronectin synthesis in target organs of diabetic complications. American Journal of Physiology –Endocrinology and Metabolism 284, E1089-1097CrossRefGoogle ScholarPubMed
43Chen, S. et al. (2003) High glucose-induced, endothelin-dependent fibronectin synthesis is mediated via NF-kappa B and AP-1. American Journal of Physiology – Cell Physiology 284, C263-272CrossRefGoogle ScholarPubMed
44Weigert, C. et al. (2003) Evidence for a novel TGF-beta1-independent mechanism of fibronectin production in mesangial cells overexpressing glucose transporters. Diabetes 52, 527-535CrossRefGoogle ScholarPubMed
45Huang, Y. et al. (2008) A PAI-1 mutant, PAI-1R, slows progression of diabetic nephropathy. Journal of the American Society of Nephrology 19, 329-338CrossRefGoogle ScholarPubMed
46Nam, J.S. et al. (2008) The activation of NF-kappaB and AP-1 in peripheral blood mononuclear cells isolated from patients with diabetic nephropathy. Diabetes Research and Clinical Practice 81, 25-32CrossRefGoogle ScholarPubMed
47Goldberg, H.J., Scholey, J. and Fantus, I.G. (2000) Glucosamine activates the plasminogen activator inhibitor 1 gene promoter through Sp1 DNA binding sites in glomerular mesangial cells. Diabetes 49, 863-871CrossRefGoogle ScholarPubMed
48Goldberg, H.J. et al. (2006) Posttranslational, reversible O-glycosylation is stimulated by high glucose and mediates plasminogen activator inhibitor-1 gene expression and Sp1 transcriptional activity in glomerular mesangial cells. Endocrinology 147, 222-231CrossRefGoogle ScholarPubMed
49Vulin, A.I. and Stanley, F.M. (2004) Oxidative stress activates the plasminogen activator inhibitor type 1 (PAI-1) promoter through an AP-1 response element and cooperates with insulin for additive effects on PAI-1 transcription. Journal of Biological Chemistry 279, 25172-25178CrossRefGoogle ScholarPubMed
50Nicholas, S.B. et al. (2005) Plasminogen activator inhibitor-1 deficiency retards diabetic nephropathy. Kidney International 67, 1297-1307CrossRefGoogle ScholarPubMed
51Ahn, J.D. et al. (2001) Transcription factor decoy for activator protein-1 (AP-1) inhibits high glucose- and angiotensin II-induced type 1 plasminogen activator inhibitor (PAI-1) gene expression in cultured human vascular smooth muscle cells. Diabetologia 44, 713-720CrossRefGoogle ScholarPubMed
52Suzuki, M., Akimoto, K. and Hattori, Y. (2002) Glucose upregulates plasminogen activator inhibitor-1 gene expression in vascular smooth muscle cells. Life Sciences 72, 59-66CrossRefGoogle ScholarPubMed
53Jung, D.S. et al. (2008) FR167653 inhibits fibronectin expression and apoptosis in diabetic glomeruli and in high-glucose-stimulated mesangial cells. American Journal of Physiology – Renal Physiology 295, F595-604CrossRefGoogle ScholarPubMed
54Bowlus, C.L., McQuillan, J.J. and Dean, D.C. (1991) Characterization of three different elements in the 5′-flanking region of the fibronectin gene which mediate a transcriptional response to cAMP. Journal of Biological Chemistry 266, 1122-1127CrossRefGoogle ScholarPubMed
55Barrera, L.O. and Ren, B. (2006) The transcriptional regulatory code of eukaryotic cells–insights from genome-wide analysis of chromatin organization and transcription factor binding. Current Opinion in Cell Biology 18, 291-298CrossRefGoogle ScholarPubMed
56Wahab, N.A. et al. (2000) The decorin high glucose response element and mechanism of its activation in human mesangial cells. Journal of the American Society of Nephrology 11, 1607-1619CrossRefGoogle ScholarPubMed
57Singh, L.P. et al. (2001) Hexosamine-induced fibronectin protein synthesis in mesangial cells is associated with increases in cAMP responsive element binding (CREB) phosphorylation and nuclear CREB: the involvement of protein kinases A and C. Diabetes 50, 2355-2362CrossRefGoogle ScholarPubMed
58Kim, Y.S. et al. (2003) Differential behavior of mesangial cells derived from 12/15-lipoxygenase knockout mice relative to control mice. Kidney International 64, 1702-1714CrossRefGoogle ScholarPubMed
59Williams, K.J. et al. (2007) Decorin deficiency enhances progressive nephropathy in diabetic mice. American Journal of Pathology 171, 1441-1450CrossRefGoogle ScholarPubMed
60Sharma, S., Kulkarni, S.K. and Chopra, K. (2006) Curcumin, the active principle of turmeric (Curcuma longa), ameliorates diabetic nephropathy in rats. Clinical and Experimental Pharmacology and Physiology 33, 940-945CrossRefGoogle ScholarPubMed
61Aramburu, J. et al. (2006) Regulation of the hypertonic stress response and other cellular functions by the Rel-like transcription factor NFAT5. Biochemical Pharmacology 72, 1597-1604CrossRefGoogle ScholarPubMed
62Macian, F., Lopez-Rodriguez, C. and Rao, A. (2001) Partners in transcription: NFAT and AP-1. Oncogene 20, 2476-2489CrossRefGoogle ScholarPubMed
63Hoffmann, A., Natoli, G. and Ghosh, G. (2006) Transcriptional regulation via the NF-kappaB signaling module. Oncogene 25, 6706-6716CrossRefGoogle ScholarPubMed
64Zabel, U., Schreck, R. and Baeuerle, P.A. (1991) DNA binding of purified transcription factor NF-kappa B. Affinity, specificity, Zn2+ dependence, and differential half-site recognition. Journal of Biological Chemistry 266, 252-260CrossRefGoogle ScholarPubMed
65Mezzano, S. et al. (2004) NF-kappaB activation and overexpression of regulated genes in human diabetic nephropathy. Nephrology Dialysis Transplantation 19, 2505-2512CrossRefGoogle ScholarPubMed
66Guijarro, C. and Egido, J. (2001) Transcription factor-kappa B (NF-kappa B) and renal disease. Kidney International 59, 415-424CrossRefGoogle ScholarPubMed
67Nagarajan, R.P. et al. (2000) Repression of transforming-growth-factor-beta-mediated transcription by nuclear factor kappaB. The Biochemical Journal 348, 591-596CrossRefGoogle ScholarPubMed
68Ha, H. et al. (2002) Role of high glucose-induced nuclear factor-kappaB activation in monocyte chemoattractant protein-1 expression by mesangial cells. Journal of the American Society of Nephrology 13, 894-902CrossRefGoogle ScholarPubMed
69Gilmore, T.D. (2006) Introduction to NF-kappaB: players, pathways, perspectives. Oncogene 25, 6680-6684CrossRefGoogle Scholar
70Yang, B. et al. (2008) High glucose induction of DNA-binding activity of the transcription factor NFkappaB in patients with diabetic nephropathy. Biochimica et Biophysica Acta 1782, 295-302CrossRefGoogle ScholarPubMed
71Hofmann, M.A. et al. (1999) Peripheral blood mononuclear cells isolated from patients with diabetic nephropathy show increased activation of the oxidative-stress sensitive transcription factor NF-kappaB. Diabetologia 42, 222-232CrossRefGoogle ScholarPubMed
72Rovin, B.H. et al. (1995) Activation of nuclear factor-kappa B correlates with MCP-1 expression by human mesangial cells. Kidney International 48, 1263-1271CrossRefGoogle ScholarPubMed
73Brownlee, M. (2001) Biochemistry and molecular cell biology of diabetic complications. Nature 414, 813-820CrossRefGoogle ScholarPubMed
74El-Osta, A. et al. (2008) Transient high glucose causes persistent epigenetic changes and altered gene expression during subsequent normoglycemia. Journal of Experimental Medicine 205, 2409-2417CrossRefGoogle ScholarPubMed
75Hofmann, M.A. et al. (1998) Insufficient glycemic control increases nuclear factor-kappa B binding activity in peripheral blood mononuclear cells isolated from patients with type 1 diabetes. Diabetes Care 21, 1310-1316CrossRefGoogle ScholarPubMed
76Schmid, H. et al. (2006) Modular activation of nuclear factor-kappaB transcriptional programs in human diabetic nephropathy. Diabetes 55, 2993-3003CrossRefGoogle ScholarPubMed
77Park, C.W. et al. (2000) High glucose-induced intercellular adhesion molecule-1 (ICAM-1) expression through an osmotic effect in rat mesangial cells is PKC-NF-kappa B-dependent. Diabetologia 43, 1544-1553CrossRefGoogle ScholarPubMed
78Kiritoshi, S. et al. (2003) Reactive oxygen species from mitochondria induce cyclooxygenase-2 gene expression in human mesangial cells: potential role in diabetic nephropathy. Diabetes 52, 2570-2577CrossRefGoogle ScholarPubMed
79Zhang, M., Fraser, D. and Phillips, A. (2006) ERK, p38, and Smad signaling pathways differentially regulate transforming growth factor-beta1 autoinduction in proximal tubular epithelial cells. American Journal of Pathology 169, 1282-1293CrossRefGoogle ScholarPubMed
80Jiang, T. et al. (2008) Transcription factor AP-1 regulates TGF-beta(1)-induced expression of aldose reductase in cultured human mesangial cells. Nephrology (Carlton) 13, 212-217CrossRefGoogle ScholarPubMed
81Olmos, P. et al. (1999) [Aldose reductase gene polymorphism and rate of appearance of retinopathy in non insulin dependent diabetics.] Revista Medica de Chile 127, 399-409 [Article in Spanish]Google ScholarPubMed
82Yang, B. et al. (2006) Elevated activity of transcription factor nuclear factor of activated T-cells 5 (NFAT5) and diabetic nephropathy. Diabetes 55, 1450-1455CrossRefGoogle ScholarPubMed
83Jiang, T. et al. (2006) Aldose reductase regulates TGF-beta1-induced production of fibronectin and type IV collagen in cultured rat mesangial cells. Nephrology (Carlton) 11, 105-112CrossRefGoogle ScholarPubMed
84Zhang, Z. et al. (2007) 1,25-Dihydroxyvitamin D3 targeting of NF-kappaB suppresses high glucose-induced MCP-1 expression in mesangial cells. Kidney International 72, 193-201CrossRefGoogle ScholarPubMed
85Giunti, S. et al. (2008) Monocyte chemoattractant protein-1 has prosclerotic effects both in a mouse model of experimental diabetes and in vitro in human mesangial cells. Diabetologia 51, 198-207CrossRefGoogle Scholar
86Kanamori, H. et al. (2007) Inhibition of MCP-1/CCR2 pathway ameliorates the development of diabetic nephropathy. Biochemical and Biophysical Research Communications 360, 772-777CrossRefGoogle ScholarPubMed
87Tesch, G.H. (2008) MCP-1/CCL2: a new diagnostic marker and therapeutic target for progressive renal injury in diabetic nephropathy. American Journal of Physiology – Renal Physiology 294, F697-701CrossRefGoogle ScholarPubMed
88Park, J. et al. (2008) MCP-1/CCR2 system is involved in high glucose-induced fibronectin and type IV collagen expression in cultured mesangial cells. American Journal of Physiology – Renal Physiology 295, F749-757CrossRefGoogle ScholarPubMed
89Banba, N. et al. (2000) Possible relationship of monocyte chemoattractant protein-1 with diabetic nephropathy. Kidney International 58, 684-690CrossRefGoogle ScholarPubMed
90Li, Y. et al. (2008) Role of the histone H3 lysine 4 methyltransferase, SET7/9, in the regulation of NF-kappaB-dependent inflammatory genes. Relevance to diabetes and inflammation. Journal of Biological Chemistry 283, 26771-26781CrossRefGoogle ScholarPubMed
91Voraberger, G., Schafer, R. and Stratowa, C. (1991) Cloning of the human gene for intercellular adhesion molecule 1 and analysis of its 5′-regulatory region. Induction by cytokines and phorbol ester. Journal of Immunology 147, 2777-2786CrossRefGoogle ScholarPubMed
92Ko, B.C. et al. (2002) Fyn and p38 signaling are both required for maximal hypertonic activation of the osmotic response element-binding protein/tonicity-responsive enhancer-binding protein (OREBP/TonEBP). Journal of Biological Chemistry 277, 46085-46092CrossRefGoogle ScholarPubMed
93Prabhu, K.S. et al. (2005) Up-regulation of human myo-inositol oxygenase by hyperosmotic stress in renal proximal tubular epithelial cells. Journal of Biological Chemistry 280, 19895-19901CrossRefGoogle ScholarPubMed
94Nayak, B. et al. (2005) Modulation of renal-specific oxidoreductase/myo-inositol oxygenase by high-glucose ambience. Proceedings of the National Academy of Sciences of the United States of America 102, 17952-17957CrossRefGoogle ScholarPubMed
95Yang, Q. et al. (2000) Identification of a renal-specific oxido-reductase in newborn diabetic mice. Proceedings of the National Academy of Sciences of the United States of America 97, 9896-9901CrossRefGoogle ScholarPubMed
96Kanwar, Y.S. et al. (2005) Renal-specific oxidoreductase biphasic expression under high glucose ambience during fetal versus neonatal development. Kidney International 68, 1670-1683CrossRefGoogle ScholarPubMed
97Kanwar, Y.S. et al. (2002) Relevance of renal-specific oxidoreductase in tubulogenesis during mammalian nephron development. American Journal of Physiology – Renal Physiology 282, F752-762CrossRefGoogle ScholarPubMed
98Kang, J.H. et al. (2008) Suppression of mesangial cell proliferation and extracellular matrix production in streptozotocin-induced diabetic rats by Sp1 decoy oligodeoxynucleotide in vitro and in vivo. Journal of Cellular Biochemistry 103, 663-674CrossRefGoogle ScholarPubMed
99Zhang, D. et al. (2008) A single nucleotide polymorphism alters the sequence of SP1 binding site in the adiponectin promoter region and is associated with diabetic nephropathy among type 1 diabetic patients in the Genetics of Kidneys in Diabetes Study. Journal of Diabetes and its Complications Jul 2; [Epub ahead of print]Google ScholarPubMed
100Chae, Y.M. et al. (2004) Sp1-decoy oligodeoxynucleotide inhibits high glucose-induced mesangial cell proliferation. Biochemical and Biophysical Research Communications 319, 550-555CrossRefGoogle ScholarPubMed
101Auro, K. et al. (2008) USF1 gene variants contribute to metabolic traits in men in a longitudinal 32-year follow-up study. Diabetologia 51, 464-472CrossRefGoogle Scholar
102Ng, M.C. et al. (2005) The linkage and association of the gene encoding upstream stimulatory factor 1 with type 2 diabetes and metabolic syndrome in the Chinese population. Diabetologia 48, 2018-2024CrossRefGoogle ScholarPubMed
103Holzapfel, C. et al. (2008) Genetic variants in the USF1 gene are associated with low-density lipoprotein cholesterol levels and incident type 2 diabetes mellitus in women: results from the MONICA/KORA Augsburg case-cohort study, 1984-2002. European Journal of Endocrinology 159, 407-416CrossRefGoogle ScholarPubMed
104Gosek, K. et al. (2005) C-106T polymorphism in promoter of aldose reductase gene is a risk factor for diabetic nephropathy in type 2 diabetes patients with poor glycaemic control. Nephron Experimental Nephrology 99, e63-67CrossRefGoogle ScholarPubMed
105Moon, J.Y. et al. (2007) Association of polymorphisms in monocyte chemoattractant protein-1 promoter with diabetic kidney failure in Korean patients with type 2 diabetes mellitus. Journal of Korean Medical Science 22, 810-814CrossRefGoogle ScholarPubMed
106Wong, T.Y. et al. (2000) Association of plasminogen activator inhibitor-1 4G/4G genotype and type 2 diabetic nephropathy in Chinese patients. Kidney International 57, 632-638CrossRefGoogle ScholarPubMed
107Ahn, J.D. et al. (2004) Transcription factor decoy for AP-1 reduces mesangial cell proliferation and extracellular matrix production in vitro and in vivo. Gene Therapy 11, 916-923CrossRefGoogle ScholarPubMed
108Matsuda, H. et al. (2006) Development of gene silencing pyrrole-imidazole polyamide targeting the TGF-beta1 promoter for treatment of progressive renal diseases. Journal of the American Society of Nephrology 17, 422-432CrossRefGoogle ScholarPubMed
109Shishodia, S., Singh, T. and Chaturvedi, M.M. (2007) Modulation of transcription factors by curcumin. Advances in Experimental Medicine and Biology 595, 127-148CrossRefGoogle ScholarPubMed
110McGowan, T.A., Zhu, Y. and Sharma, K. (2004) Transforming growth factor-beta: a clinical target for the treatment of diabetic nephropathy. Current Diabetes Reports 4, 447-454CrossRefGoogle ScholarPubMed
111Nakanishi, H. et al. (2004) Pirfenidone inhibits the induction of iNOS stimulated by interleukin-1beta at a step of NF-kappaB DNA binding in hepatocytes. Journal of Hepatology 41, 730-736CrossRefGoogle Scholar
112Tikoo, K. et al. (2008) Change in histone H3 phosphorylation, MAP kinase p38, SIR 2 and p53 expression by resveratrol in preventing streptozotocin induced type I diabetic nephropathy. Free Radical Research 42, 397-404CrossRefGoogle ScholarPubMed
113Pearson, K.J. et al. (2008) Resveratrol delays age-related deterioration and mimics transcriptional aspects of dietary restriction without extending life span. Cell Metabolism 8, 157-168CrossRefGoogle ScholarPubMed
114Tikoo, K. et al. (2008) Change in post-translational modifications of histone H3, heat-shock protein-27 and MAP kinase p38 expression by curcumin in streptozotocin-induced type I diabetic nephropathy. British Journal of Pharmacology 153, 1225-1231CrossRefGoogle ScholarPubMed
115Lee, H.B. et al. (2007) Histone deacetylase inhibitors: a novel class of therapeutic agents in diabetic nephropathy. Kidney International Supplement S61-66CrossRefGoogle ScholarPubMed

Further reading, resources and contacts

The Animal Models of Diabetic Complications Consortium website is a useful resource for investigators in this field:

Brivanlou, A.H. and Darnell, J.E. Jr (2002) Signal transduction and the control of gene expression. Science 295, 813-818CrossRefGoogle ScholarPubMed
Brownlee, M. (2001) Biochemistry and molecular cell biology of diabetic complications. Nature 414, 813-820CrossRefGoogle ScholarPubMed
Zhu, Y., Usui, H.K. and Sharma, K. (2007) Regulation of transforming growth factor beta in diabetic nephropathy: implications for treatment. Seminars in Nephrology 27, 153-160CrossRefGoogle ScholarPubMed
Zhu, Y. et al. (2005) Role of upstream stimulatory factors in regulation of renal transforming growth factor-beta1. Diabetes 54, 1976-1984CrossRefGoogle ScholarPubMed
Brivanlou, A.H. and Darnell, J.E. Jr (2002) Signal transduction and the control of gene expression. Science 295, 813-818CrossRefGoogle ScholarPubMed
Brownlee, M. (2001) Biochemistry and molecular cell biology of diabetic complications. Nature 414, 813-820CrossRefGoogle ScholarPubMed
Zhu, Y., Usui, H.K. and Sharma, K. (2007) Regulation of transforming growth factor beta in diabetic nephropathy: implications for treatment. Seminars in Nephrology 27, 153-160CrossRefGoogle ScholarPubMed
Zhu, Y. et al. (2005) Role of upstream stimulatory factors in regulation of renal transforming growth factor-beta1. Diabetes 54, 1976-1984CrossRefGoogle ScholarPubMed